^
    17h
    PEMIGIST: PH 2 Pemigatinib in SDH-deficient GIST (clinicaltrials.gov)
    P2, N=24, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Pemazyre (pemigatinib)
    18h
    Ph 2 Elacestrant in ER Positive Uterine Sarcomas (clinicaltrials.gov)
    P2, N=30, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor)
    |
    Orserdu (elacestrant)
    18h
    A Study in Adults With Desmoid Tumors (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Elpiscience (Suzhou) Biopharma, Ltd.
    New P2 trial
    20h
    ISOMUTAR: Functional Outcomes of Knee Protheses for Malignant Tumours of Bone (clinicaltrials.gov)
    P=N/A, N=9, Completed, University Hospital, Lille | Terminated --> Completed
    Trial completion
    1d
    Aerosolized Aldesleukin in Treating Patients With Lung Metastases (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    |
    Proleukin (aldesleukin)
    1d
    Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    1d
    Liver Ewing sarcoma: A case report. (PubMed, Radiol Case Rep)
    Histology and immunohistochemistry (CD99 +, INI-1 +, NKX2.2 +, Ki-67 ≈ 60%) confirmed the diagnosis. This is the first Moroccan and the seventh case of primary hepatic ES reported in the literature, emphasizing the need to consider this entity in the differential diagnosis of pediatric liver tumors.
    Journal
    |
    CD99 (CD99 Molecule)
    1d
    Manganese-potentiated cGAS-STING activation with ATM/PRMT5 inhibition remodels the immunosuppressive microenvironment in osteosarcoma via bone-targeted delivery. (PubMed, Bioact Mater)
    To overcome these hurdles, we developed a bone-targeted, glutathione (GSH)-responsive polymeric nanoparticle (NPALN/Mn-AP) that chelates manganese (Mn) and delivers an ATM inhibitor (AZD0156) and a PRMT5 inhibitor (GSK3326595). By functionalizing this nanoplatform with alendronate (ALN) into NPALN/Mn-AP, we achieve preferential accumulation in bone tumors...In vivo studies demonstrate that NPALN/Mn-AP significantly inhibits OS progression and boosts systemic immune responses. This dual-action, bone-specific nanotherapeutic platform synchronized DNA-repair inhibition and Mn-enhanced immune-stimulation, offering a promising new approach for effective osteosarcoma treatment.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    pemrametostat (GSK3326595) • AZD0156
    1d
    CBX3 promotes epithelial-mesenchymal transition in synovial sarcoma via the SHH signaling pathway. (PubMed, Am J Cancer Res)
    Mechanistically, CBX3 binds directly to and SHH and prevents its ubiquitin-mediated degradation, thereby stabilizing the protein. CBX3-SHH subsequently suppresses mitochondrial oxidative metabolism, which in turn inhibits ferroptosis and facilitates EMT - ultimately promoting SS aggressiveness.
    Journal
    |
    GLI1 (GLI Family Zinc Finger 1) • SHH (Sonic Hedgehog Signaling Molecule) • CBX3 (Chromobox 3)
    1d
    Carbon-ion beam irradiation combined with miR-17-5p/miR-17-3p inhibitors effectively kill osteosarcoma cells. (PubMed, Am J Cancer Res)
    In addition, combination treatment with miR-17-5p/miR-17-3p inhibitors and carbon-ion beam IR significantly increased the number of γH2AX foci as well as its phosphorylation. Taken together, miR-17-5p/miR-17-3p inhibitors enhanced the carbon-ion beam radiosensitivity of OS cells, presenting a novel strategy for the development of carbon-ion beam combination therapy.
    Journal • PARP Biomarker
    |
    CASP3 (Caspase 3) • MIR17 (MicroRNA 17)
    1d
    NTRK Gene Fusions in Pediatric Soft-Tissue Tumors: Diagnostic Significance and Clinical Decision-making. (PubMed, Curr Pediatr Rev)
    NTRK gene fusions are a critical marker for pediatric soft tissue tumors and are used for precision medicine in these tumors. NTRK gene fusions are used as diagnostic markers for infantile fibrosarcoma, congenital mesoblastic nephroma, and secretory carcinomas, and they play a critical role in the management of these tumors.
    Journal
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
    1d
    An In-Vitro Laboratory Exploration Revealed the Antitumor Effects of Melittin on Osteosarcoma CVCells. (PubMed, Curr Med Chem)
    The research demonstrated the anti-OS effects of melittin and its possible relationship with the PI3K/AKT/mTOR pathway.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)